IPQ Inside the global regulatory dialogue

FDA Seeing Wide Variation in Drug Application Manufacturing Submissions, Causing Approval Delays

Jul 6th, 2010

Please Log in to print the full article

Manufacturing information that is inaccurate, incomplete, inconsistent, or in the wrong section in new and abbreviated new drug applications (NDAs/ANDAs) as well as facilities not being ready for an inspection continue to be problem areas...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2021 IPQ Publications